Human Cathelicidin
Human Cathelicidin | Antimicrobial Peptide
DoseGear research brief
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from hCAP18 that exhibits broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while modulating immune responses.
Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic exposure when used topically.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Human cathelicidin-derived antimicrobial peptide.
Host defense, inflammation, and wound repair through membrane interactions and context-dependent immune-cell signaling.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Chart reference | 50 mcg | Daily · See source guide | Injectable · 5 mg lyophilized vial + 3 mL BAC Water |
Reference cycle
2-8 weeks depending on wound healing progress
Reference storage
Lyophilized: 2-8°C; Reconstituted: 2-8°C, maintain sterility
Venous Leg Ulcer Trial - Grönberg et al.
Melanoma Phase I Trial
MRSA Biofilm Study - Noore et al.
Structural Analysis - Wang et al.
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
